MX345700B - Proteinas f del vrs modificadas y metodos de uso de las mismas. - Google Patents

Proteinas f del vrs modificadas y metodos de uso de las mismas.

Info

Publication number
MX345700B
MX345700B MX2016003771A MX2016003771A MX345700B MX 345700 B MX345700 B MX 345700B MX 2016003771 A MX2016003771 A MX 2016003771A MX 2016003771 A MX2016003771 A MX 2016003771A MX 345700 B MX345700 B MX 345700B
Authority
MX
Mexico
Prior art keywords
proteins
methods
modified rsv
modified
rsv
Prior art date
Application number
MX2016003771A
Other languages
English (en)
Spanish (es)
Inventor
Smith Gale
Wu Yingyun
Massare Michael
Liu Ye
Pushko Peter
Zhou Bin
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX345700(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX345700B publication Critical patent/MX345700B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016003771A 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas. MX345700B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US16907709P 2009-04-14 2009-04-14
US22478709P 2009-07-10 2009-07-10
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (1)

Publication Number Publication Date
MX345700B true MX345700B (es) 2017-02-10

Family

ID=42310119

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2011006205A MX2011006205A (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2017001924A MX358836B (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2014011966A MX337932B (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2016003771A MX345700B (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2011006205A MX2011006205A (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2017001924A MX358836B (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2014011966A MX337932B (es) 2008-12-09 2009-12-09 Proteinas f del vrs modificadas y metodos de uso de las mismas.

Country Status (23)

Country Link
US (7) US8715692B2 (pt)
EP (3) EP2370099B1 (pt)
JP (4) JP5813513B2 (pt)
KR (2) KR101801213B1 (pt)
CN (2) CN102307591B (pt)
AU (1) AU2009333484B2 (pt)
BR (1) BRPI0922867B8 (pt)
CA (1) CA2746228C (pt)
CY (2) CY1117757T1 (pt)
DK (2) DK2370099T3 (pt)
ES (2) ES2582005T3 (pt)
HK (1) HK1161690A1 (pt)
HR (2) HRP20160859T1 (pt)
HU (2) HUE051666T2 (pt)
IL (2) IL213450B (pt)
LT (1) LT3067064T (pt)
MX (4) MX2011006205A (pt)
PL (2) PL3067064T3 (pt)
PT (2) PT2370099T (pt)
RU (1) RU2531510C2 (pt)
SG (2) SG172022A1 (pt)
SI (2) SI2370099T1 (pt)
WO (1) WO2010077717A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
US20120093855A1 (en) * 2008-11-18 2012-04-19 Ligocyte Pharmaceuticals, Inc. RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN102639147B (zh) * 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
WO2011046925A1 (en) * 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
MX354750B (es) * 2010-11-05 2018-03-20 Novavax Inc PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
WO2013019800A1 (en) * 2011-08-01 2013-02-07 Emory University Vlps containing ligands and methods related thereto
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
MX2014003777A (es) * 2011-09-30 2015-05-15 Novavax Inc Vacuna de nanoparticulas de proteinas f del rsv recombinantes para el virus respiratorio sincitial.
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
BR112015002131B1 (pt) * 2012-08-01 2022-11-01 Bavarian Nordic A/S Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
US20150329597A1 (en) 2012-11-20 2015-11-19 Andrea Carfi Rsv f prefusion trimers
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
SG10201802194WA (en) 2013-09-19 2018-05-30 Novavax Inc Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
EP3177720B1 (en) * 2014-08-08 2021-09-22 VLP Therapeutics, Inc. Virus like particle comprising modified envelope protein e3
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
BR112018004242A2 (pt) 2015-09-03 2018-09-25 Novavax Inc composições de vacina que possuem estabilidade e imunogenicidade aumentadas
BR112018010805A2 (pt) 2015-12-23 2018-11-27 Pfizer Inc. mutantes de proteína f de rsv
AU2017248018A1 (en) * 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
AU2017272504A1 (en) 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
CA3057171A1 (en) * 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
CN110603262A (zh) 2017-04-04 2019-12-20 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
BR112019026434A2 (pt) 2017-06-14 2020-07-14 Virometix Ag peptídeos cíclicos para proteção contra vírus sincicial respiratório
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
AU2019228551A1 (en) 2018-02-28 2020-10-15 University Of Washington Self-assembling nanostructure vaccines
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US11576960B2 (en) * 2018-03-30 2023-02-14 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (RSV) vaccines
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
KR102725189B1 (ko) 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
EP3897708A1 (en) 2018-12-20 2021-10-27 Virometix AG Lipopeptide building blocks and synthetic virus-like particles
KR102679227B1 (ko) 2019-02-28 2024-06-28 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3165371A1 (en) * 2020-01-27 2021-08-05 Gale Smith Coronavirus vaccine formulations
BR112022019781A2 (pt) 2020-04-22 2022-12-13 BioNTech SE Vacina para o coronavírus
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115927751A (zh) * 2022-09-17 2023-04-07 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560A (zh) * 2024-07-09 2024-08-13 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
AU4346101A (en) 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
CZ2003930A3 (cs) 2000-10-02 2003-08-13 Glaxosmithkline Biologicals S. A. Vakcinační prostředek obsahující štěpený virus s obalem
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
AU2004273776B2 (en) 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2005021713A2 (en) * 2003-06-20 2005-03-10 Protein Sciences Corporation Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
WO2005080417A2 (en) 2003-12-10 2005-09-01 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
CN101548009A (zh) 2005-03-10 2009-09-30 米迪缪尼有限公司 偏肺病毒株及其在疫苗制备和作为抗原序列表达载体的应用以及增殖该病毒的方法
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2040746A4 (en) 2006-06-19 2009-12-16 Progenics Pharm Inc METHODS OF RECOVERING STABILIZED FORMULATIONS OF RETROVIRAL ENVELOPE (ENV) PROTEIN TRIMERS
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
US20100203071A1 (en) 2007-03-21 2010-08-12 Norman Blais Chimeric antigens
EP2540312B1 (en) 2007-07-19 2015-04-15 Novavax, Inc. Avian influenza chimeric VLPS
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
WO2009108689A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
EA023054B1 (ru) * 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
CN102639147B (zh) * 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
MX354750B (es) 2010-11-05 2018-03-20 Novavax Inc PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
MX2014003777A (es) 2011-09-30 2015-05-15 Novavax Inc Vacuna de nanoparticulas de proteinas f del rsv recombinantes para el virus respiratorio sincitial.
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
KR20150138184A (ko) 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
ES2715378T3 (es) 2013-04-25 2019-06-04 Janssen Vaccines & Prevention Bv Polipéptidos F de prefusión del virus sincicial respiratorio (RSV) solubles y estabilizados
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
BR112018004242A2 (pt) 2015-09-03 2018-09-25 Novavax Inc composições de vacina que possuem estabilidade e imunogenicidade aumentadas

Also Published As

Publication number Publication date
US20100239617A1 (en) 2010-09-23
JP2015171378A (ja) 2015-10-01
US20150265698A1 (en) 2015-09-24
IL213450B (en) 2018-02-28
JP2018007655A (ja) 2018-01-18
US8715692B2 (en) 2014-05-06
HK1161690A1 (zh) 2012-08-03
KR20110112328A (ko) 2011-10-12
PL3067064T3 (pl) 2020-11-02
ES2796725T3 (es) 2020-11-30
US20190134187A1 (en) 2019-05-09
JP5813513B2 (ja) 2015-11-17
RU2011128371A (ru) 2013-01-20
LT3067064T (lt) 2020-09-10
SG172022A1 (en) 2011-07-28
BRPI0922867A2 (pt) 2016-09-27
JP2012511579A (ja) 2012-05-24
MX2011006205A (es) 2011-09-01
DK3067064T3 (da) 2020-06-08
EP3718566B1 (en) 2024-06-12
SI3067064T1 (sl) 2020-09-30
EP3718566A1 (en) 2020-10-07
US20140294879A1 (en) 2014-10-02
HUE051666T2 (hu) 2021-03-29
US11052146B2 (en) 2021-07-06
SI2370099T1 (sl) 2016-08-31
PT3067064T (pt) 2020-06-16
KR20160148720A (ko) 2016-12-26
CA2746228A1 (en) 2010-07-08
CA2746228C (en) 2021-05-18
JP2019069982A (ja) 2019-05-09
EP2370099B1 (en) 2016-04-20
CN106146671B (zh) 2020-03-31
IL213450A0 (en) 2011-07-31
MX358836B (es) 2018-09-05
PT2370099T (pt) 2016-07-14
JP6462048B2 (ja) 2019-01-30
US20150359872A1 (en) 2015-12-17
US9675685B2 (en) 2017-06-13
HUE029037T2 (en) 2017-01-30
EP2370099A1 (en) 2011-10-05
AU2009333484B2 (en) 2014-12-11
JP6782289B2 (ja) 2020-11-11
HRP20160859T1 (hr) 2016-09-23
US20230293667A1 (en) 2023-09-21
WO2010077717A1 (en) 2010-07-08
BRPI0922867B8 (pt) 2021-05-25
CN102307591B (zh) 2016-08-03
BRPI0922867B1 (pt) 2020-09-29
ES2582005T3 (es) 2016-09-08
IL247341B (en) 2018-04-30
RU2531510C2 (ru) 2014-10-20
US20150266930A1 (en) 2015-09-24
CY1123152T1 (el) 2021-10-29
CN106146671A (zh) 2016-11-23
CY1117757T1 (el) 2017-05-17
CN102307591A (zh) 2012-01-04
MX337932B (es) 2016-03-28
KR101691574B1 (ko) 2017-01-02
AU2009333484A1 (en) 2011-07-21
EP3067064B1 (en) 2020-05-13
DK2370099T3 (en) 2016-08-01
HRP20200871T1 (hr) 2020-10-30
SG10201500161XA (en) 2015-03-30
EP3067064A1 (en) 2016-09-14
PL2370099T3 (pl) 2016-10-31
US9731000B2 (en) 2017-08-15
US9717786B2 (en) 2017-08-01
KR101801213B1 (ko) 2017-11-24
JP6162751B2 (ja) 2017-07-12
US10022437B2 (en) 2018-07-17
EP2370099A4 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
EA201070794A1 (ru) Рекомбинантные антигены rsv
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
MY201791A (en) Stabilized soluble pre-fusion rsv f polypeptides
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
MX2012000036A (es) Vacuna.
EA201690031A1 (ru) Стабилизированные растворимые f-полипептиды rsv перед слиянием
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
MX2014009933A (es) Diaminopirimidinas utiles como inhibidores del virus sincitial respiratorio humano (rsv).
TR201905336T4 (tr) Rekombinant rsv antijenleri.
WO2011002423A3 (en) Solubility enhancing pharmaceutical composition
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease